Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -11,00k | 2,53M | Derivative Exercise and Sale | 229,85 | 24,91k | - |
| 2026-05-01 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | 14,25k | 0,00 | Derivative Exercise and Retained Stock | - | 24,91k | 133,73% |
| 2026-02-27 | Mr. Robert J. DeckerController & CAO | -4,08k | 538,72k | Derivative Exercise and Sale | 115,67 - 247,87 | 24,46k | - |
| 2026-02-20 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -1,32k | 324,76k | Vente | 245,66 | 26,24k | -4,80% |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | 11,06k | 0,00 | Derivative Exercise and Retained Stock | - | 25,70k | 75,56% |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | -62,08k | 4,91M | Derivative Exercise and Sale | 162,75 - 243,76 | 25,70k | - |
| 2026-02-13 | Mr. James SwansonExec. VP & Chief Information Officer | -4,21k | 1,03M | Sale to Issuer | 243,45 - 244,55 | 25,70k | -14,09% |
| 2026-02-13 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | 9,49k | 0,00 | Derivative Exercise and Retained Stock | - | 23,00k | 70,28% |
| 2026-02-15 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -526,00 | 128,04k | Derivative Exercise and Sale | 243,39 - 243,45 | 23,00k | - |
| 2026-02-17 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -5,94k | 1,45M | Vente | 243,39 | 23,00k | -20,53% |
| 2026-02-13 | Ms. Vanessa BroadhurstExec. VP of Global Corporate Affairs | -4,14k | 1,01M | Sale to Issuer | 243,45 - 244,55 | 23,00k | -15,27% |
| 2026-02-13 | Mr. Joaquin DuatoCEO & Chairman | 48,48k | 0,00 | Derivative Exercise and Retained Stock | - | 356,30k | 15,75% |
| 2026-02-13 | Mr. Joaquin DuatoCEO & Chairman | -36,23k | 8,86M | Derivative Exercise and Sale | 243,45 - 244,55 | 356,30k | - |
| 2026-02-13 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | 16,44k | 0,00 | Derivative Exercise and Retained Stock | - | 194,45k | 9,23% |
| 2026-02-13 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | -15,72k | 3,84M | Derivative Exercise and Sale | 243,45 - 244,55 | 194,45k | - |
| 2026-02-13 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | 6,93k | 0,00 | Derivative Exercise and Retained Stock | - | 27,56k | 33,60% |
| 2026-02-18 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -22,62k | 2,79M | Derivative Exercise and Sale | 115,67 - 244,53 | 27,56k | - |
| 2026-02-13 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -2,29k | 558,78k | Sale to Issuer | 243,45 - 244,55 | 27,56k | -7,66% |
| 2026-02-13 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 8,02k | 0,00 | Derivative Exercise and Retained Stock | - | 23,57k | 51,58% |
| 2026-02-13 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -8,36k | 2,04M | Derivative Exercise and Sale | 243,45 - 244,55 | 23,57k | - |
| 2026-02-13 | Mr. Robert J. DeckerController & CAO | 2,68k | 0,00 | Derivative Exercise and Retained Stock | - | 24,46k | 12,31% |
| 2026-02-13 | Mr. Robert J. DeckerController & CAO | -1,06k | 257,79k | Derivative Exercise and Sale | 243,45 - 244,55 | 24,46k | - |
| 2026-02-15 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -54,84k | 5,22M | Derivative Exercise and Sale | 156,15 - 243,45 | 10,66k | - |
| 2026-02-13 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | 3,42k | 0,00 | Derivative Exercise and Retained Stock | - | 19,83k | 20,85% |
| 2026-02-13 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | -1,59k | 387,15k | Derivative Exercise and Sale | 243,45 - 244,55 | 19,83k | - |
| 2026-02-13 | Mr. Joseph James WolkExec. VP & CFO | -107,78k | 18,01M | Derivative Exercise and Sale | 115,67 - 244,55 | 85,01k | - |
| 2026-02-13 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 114,66k | 7,84% |
| 2026-02-13 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | -7,27k | 1,78M | Derivative Exercise and Sale | 243,45 - 244,55 | 114,66k | - |
| 2026-02-06 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | 5,24k | 533,39k | Derivative Exercise and Retained Stock | 101,87 | 22,92k | 29,62% |
| 2026-02-06 | Mr. Timothy SchmidExec. VP & Worldwide Chairman of MedTech | -10,34k | 1,43M | Derivative Exercise and Sale | 101,87 - 239,99 | 22,92k | - |
| 2026-02-06 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | 2,29k | 233,28k | Derivative Exercise and Retained Stock | 101,87 | 16,41k | 16,22% |
| 2026-02-06 | Ms. Kristen Blair MulhollandExec. VP & Chief HR Officer | -3,34k | 460,63k | Derivative Exercise and Sale | 101,87 - 239,99 | 16,41k | - |
| 2026-02-06 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | 11,68k | 1,19M | Derivative Exercise and Retained Stock | 101,87 | 106,32k | 12,34% |
| 2026-02-06 | Ms. Kathryn E. WengelExec. VP and Chief Technical Operations & Risk Officer | -27,27k | 3,77M | Derivative Exercise and Sale | 101,87 - 239,99 | 106,32k | - |
| 2026-02-05 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 2,70k | 349,03k | Derivative Exercise and Retained Stock | 129,51 | 15,55k | 20,97% |
| 2026-02-05 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -6,23k | 674,84k | Derivative Exercise and Sale | 129,51 - 237,90 | 15,55k | - |
| 2023-08-23 | Dr. Paula A. JohnsonIndependent Director | -11,00 | 0,00 | Sale to Issuer | - | 89,00 | -11,00% |
| 2026-01-26 | Mr. Joaquin DuatoCEO & Chairman | -100,00k | 22,12M | Vente | 220,99 - 221,48 | 307,81k | -24,52% |
| 2025-11-26 | Mr. John G. MorikisDirector | 1,25k | 257,69k | Achat | 206,15 | 1,85k | 208,68% |
| 2025-10-17 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -21,72k | 755,61k | Derivative Exercise and Sale | 157,92 - 192,71 | 10,66k | - |
| 2025-09-04 | Ms. Jennifer L. TaubertExec. VP & Worldwide Chairman of Innovative Medicine | -56,47k | 4,29M | Derivative Exercise and Sale | 101,87 - 177,81 | 178,01k | - |
| 2025-08-29 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | 1,95k | 225,67k | Derivative Exercise and Retained Stock | 115,67 | 12,85k | 17,90% |
| 2025-08-29 | Ms. Elizabeth ForminardExec. VP & Chief Legal Officer | -9,57k | 588,84k | Derivative Exercise and Sale | 115,67 - 177,20 | 12,85k | - |
| 2025-08-22 | Mr. Joaquin DuatoCEO & Chairman | -125,82k | 9,73M | Derivative Exercise and Sale | 101,87 - 179,21 | 407,79k | - |
| 2025-08-15 | Mr. Joseph James WolkExec. VP & CFO | -16,82k | 1,26M | Derivative Exercise and Sale | 101,87 - 176,91 | 84,98k | - |
| 2025-07-17 | Dr. John C. ReedExec. VP of Innovative Medicine and R&D | -19,14k | 3,13M | Vente | 163,55 | 10,66k | -64,23% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
